FI964340L - Uudet asykliset ja sykliset amidit hermoston välittäjäaineen vapautumisen tehostimina - Google Patents

Uudet asykliset ja sykliset amidit hermoston välittäjäaineen vapautumisen tehostimina Download PDF

Info

Publication number
FI964340L
FI964340L FI964340A FI964340A FI964340L FI 964340 L FI964340 L FI 964340L FI 964340 A FI964340 A FI 964340A FI 964340 A FI964340 A FI 964340A FI 964340 L FI964340 L FI 964340L
Authority
FI
Finland
Prior art keywords
enhancers
neurotransmitter release
cyclic amides
novel acyclic
acyclic
Prior art date
Application number
FI964340A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI964340A0 (fi
FI964340A7 (fi
Inventor
Robert A Volkmann
Vytautas J Jasys
Gene M Bright
Anabella Villalobos
Patricia A Seymour
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI964340A0 publication Critical patent/FI964340A0/fi
Publication of FI964340A7 publication Critical patent/FI964340A7/fi
Publication of FI964340L publication Critical patent/FI964340L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • C07D213/20—Quaternary compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C233/06—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FI964340A 1994-04-29 1995-03-20 Uudet asykliset ja sykliset amidit hermoston välittäjäaineen vapautumisen tehostimina FI964340L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23674394A 1994-04-29 1994-04-29
PCT/IB1995/000189 WO1995029909A1 (en) 1994-04-29 1995-03-20 Novel acyclic and cyclic amides as neurotransmitter release enhancers

Publications (3)

Publication Number Publication Date
FI964340A0 FI964340A0 (fi) 1996-10-28
FI964340A7 FI964340A7 (fi) 1996-10-28
FI964340L true FI964340L (fi) 1996-10-28

Family

ID=22890767

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964340A FI964340L (fi) 1994-04-29 1995-03-20 Uudet asykliset ja sykliset amidit hermoston välittäjäaineen vapautumisen tehostimina

Country Status (14)

Country Link
US (1) US5854232A (de)
EP (1) EP0757685B1 (de)
JP (4) JP3004728B2 (de)
AT (1) ATE271553T1 (de)
AU (1) AU1884595A (de)
CA (1) CA2188427C (de)
DE (1) DE69533284T2 (de)
DK (1) DK0757685T3 (de)
ES (1) ES2223049T3 (de)
FI (1) FI964340L (de)
IL (1) IL113436A0 (de)
MX (1) MX9605218A (de)
PT (1) PT757685E (de)
WO (1) WO1995029909A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09183725A (ja) * 1995-09-01 1997-07-15 Pfizer Inc ガン治療用治療剤
WO1997049700A1 (en) * 1996-06-27 1997-12-31 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
PT870757E (pt) * 1997-04-10 2002-09-30 Pfizer Derivados de adamantano substituidos por fluoro
GB9716879D0 (en) * 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
US6589450B1 (en) 1997-11-25 2003-07-08 Ljubov Robertovna Bratkova Light-converting material and composition for producing the same
US6262081B1 (en) * 1998-07-10 2001-07-17 Dupont Pharmaceuticals Company Composition for and method of treating neurological disorders
JP3833532B2 (ja) * 1999-07-21 2006-10-11 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 炎症性疾患の治療において有用な小分子
US20050074487A1 (en) * 1999-12-16 2005-04-07 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
DK1302461T3 (da) * 2000-05-31 2008-01-28 Santen Pharmaceutical Co Ltd TNF-alfa-produktionsinhibitorer
US7585523B2 (en) * 2002-08-27 2009-09-08 Targeted Medical Pharma Composition and method to augment and sustain neurotransmitter production
AU2004216360B2 (en) * 2003-02-27 2009-09-17 Eisai R & D Management Co., Ltd. Pharmaceutical composition for treatment of drug dependence
ES2319539T3 (es) 2003-09-17 2009-05-08 Janssen Pharmaceutica Nv Compuestos heterociclicos condensados como moduladores del receptor de serotonina.
WO2007019083A1 (en) * 2005-08-04 2007-02-15 Janssen Pharmaceutica N.V. Pyrimidine compounds as serotonin receptor modulators
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US8168667B2 (en) 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
EP2077261A4 (de) * 2006-09-27 2010-04-14 Nissan Chemical Ind Ltd Verfahren zur herstellung einer succinimidverbindung
US8236789B2 (en) 2008-08-29 2012-08-07 Kowa Company, Ltd. 1-adamantyl azetidin-2-one derivatives and drugs containing same
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
CN108610292B (zh) * 2018-06-12 2020-11-10 清华大学 一类3,5-二取代乙内酰脲类化合物及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4216318A (en) * 1975-12-29 1980-08-05 Smith Kline & French Laboratories Limited Heterocyclic alkyl 4-pyrimidones
US5173489A (en) * 1986-04-10 1992-12-22 The Dupont Merck Pharmaceutical Co. α,α-disubstituted aromatics and heteroaromatics as cognition enhancers
US4760083A (en) * 1986-04-10 1988-07-26 E. I. Dupont De Nemours & Company 3,3-disubstituted indolines
DK0403159T3 (da) * 1989-06-14 2000-08-14 Smithkline Beecham Corp Imidazolylalkensyrer
US5006537A (en) * 1989-08-02 1991-04-09 Hoechst-Roussel Pharmaceuticals, Inc. 1,3-dihydro-1-(pyridinylamino)-2H-indol-2-ones
CA2128233A1 (en) * 1992-01-16 1993-07-22 Wendell Wilkie Wilkerson Novel neurotransmitter releasers useful for cognition enhancement
US5278162A (en) * 1992-09-18 1994-01-11 The Du Pont Merck Pharmaceutical Company 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-b]heterocyclic-2-one useful in the treatment of cognitive disorders of man
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
KR19990067704A (ko) * 1992-12-17 1999-08-25 디. 제이. 우드, 스피겔 알렌 제이 부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
TW530047B (en) * 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists

Also Published As

Publication number Publication date
JPH09506371A (ja) 1997-06-24
IL113436A0 (en) 1995-07-31
PT757685E (pt) 2004-10-29
JP3432753B2 (ja) 2003-08-04
ES2223049T3 (es) 2005-02-16
FI964340A0 (fi) 1996-10-28
CA2188427A1 (en) 1995-11-09
JPH11209374A (ja) 1999-08-03
DK0757685T3 (da) 2004-10-25
DE69533284D1 (de) 2004-08-26
JPH11217371A (ja) 1999-08-10
EP0757685A1 (de) 1997-02-12
FI964340A7 (fi) 1996-10-28
MX9605218A (es) 1997-10-31
JPH11193273A (ja) 1999-07-21
EP0757685B1 (de) 2004-07-21
WO1995029909A1 (en) 1995-11-09
ATE271553T1 (de) 2004-08-15
JP3281320B2 (ja) 2002-05-13
JP3158103B2 (ja) 2001-04-23
JP3004728B2 (ja) 2000-01-31
US5854232A (en) 1998-12-29
CA2188427C (en) 2000-06-27
AU1884595A (en) 1995-11-29
DE69533284T2 (de) 2005-07-21

Similar Documents

Publication Publication Date Title
FI964340L (fi) Uudet asykliset ja sykliset amidit hermoston välittäjäaineen vapautumisen tehostimina
FI944418A7 (fi) Kondensoituneet sykliset yhdisteet ja niiden käyttö
KR960012626A (ko) 클립 및 그 제작 방법
FI963126L (fi) Stanoliseos ja sen käyttö
BR9708600A (pt) Composicao antiaglomerante artigo absorvente e processo para preparar uma composicão antiaglomerante
FI970522L (fi) Koostumukset ja menetelmät pidennetyn paikallisanestesian aikaansaamiseksi
DE69801976D1 (de) Zusammensetzung und Gegenstand mit verbessertem Druckverformungsrest
FI955836A0 (fi) Aromaattisesti substituoidut omega-aminoalkaanihappoamidit ja alkaanihappodiamidit
BR9504592A (pt) Mistura estabilizadora composiçao e método de estabilizaçao de material orgânico
BR9408475A (pt) Pesticidas de n-(4-pirimidinil) amidas
FI954220L (fi) Yhdistelmä-mersasidiini ja sen valmistusmenetelmä
FI960483A7 (fi) Muunnettava koostumus ja menetelmät sen käyttämiseksi
DE69942816D1 (de) System und Verfahren um Webdokumente anzuzeigen
DE69122749D1 (de) Kombination aus extremitätenlaken und beinhalterung
FI942546L (fi) Menetelmä hienojakoisten ja muunnettujen tärkkelyksien valmistamiseksi
FI964031L (fi) Bentsamidijohdannainen, mainittua johdannaista sisältävät koostumukset ja sen käyttö
FI962440A7 (fi) Vitamiini D:n amiini- ja amidijohdoksia
FI963325L (fi) Inhibiinikoostumukset ja menetelmät niiden käyttämiseksi
FI954775L (fi) Uusia polysyklisiä yhdisteitä ja niiden johdoksia neurotransmittereiden vapautumista edistävinä aineina, jotka ovat käyttökelpoisia kognitiivisten häiriöiden hoidossa
FI964271A7 (fi) Menetelmä yhdisteen DX-52-1 stabiloimiseksi ja sen lyofilisoitu koostu mus
DE69724745D1 (de) Verfahren zur Herstellung von N-Hydrocarbyl-substituierten Amiden
FI964709L (fi) Kiraalisia yhdisteitä ja niiden resoluutio
FI912546A7 (fi) Kiinniruuvattava ja/tai kiinnilyötävä kiinnitin profiilikappaleiden kiinnittämistä varten
NO180311C (no) Stiftklemme for strekkramme
FI956045L (fi) Antiparasiittisina aineina käyttökelpoiset 14-substituoidut markfortiinit ja johdannaiset

Legal Events

Date Code Title Description
MA Patent expired